Precision-Engineered Dermatan Sulfate-Mimetic Glycopolymers for Multi-Targeted SARS-CoV-2 Inhibition
Marine Drugs · 2025
DOI: 10.3390/md23120486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Lihao Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs of Ministry of Education, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharma…. Hauptthemen laut MEDLINE: Antiviral Agents, Disaccharides, Polymers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Fundamental Research Funds for the Central Universities, Taishan Scholar Climbing Project.
Abstract (Originalsprache)
The ongoing COVID-19 pandemic, caused by SARS-CoV-2, continues to pose major global health challenges despite extensive vaccination efforts. Variant escape, waning immunity, and reduced vaccine efficacy in immunocompromised populations underscore the urgent need for complementary antiviral therapeutics. Here, we report the design, synthesis, and biological evaluation of precision-engineered dermatan sulfate (DS)-mimetic glycopolymers as multi-targeted inhibitors of SARS-CoV-2. Guided by molecular docking and virtual screening, sulfation at the C2 and C4 positions of iduronic acid was identified as critical for binding to the viral spike protein and inhibiting host and viral enzymes, including heparanase (HPSE) and main protease (Mpro). Chemically synthesized DS disaccharides were covalently grafted onto polymer scaffolds via a post-modification strategy, yielding glycopolymers with well-defined assembly that form uniform nanoparticles under physiological conditions. Surface plasmon resonance and pseudovirus assays revealed strong binding to the viral spike protein (KD ≈ 177 nM), potent viral neutralization, and minimal cytotoxicity. Cellular uptake studies further demonstrated efficient internalization of nanoparticles and intracellular inhibition of HPSE and Mpro. These results establish a modular, non-anticoagulant, and glycosaminoglycan-mimetic platform for the development of broad-spectrum antiviral agents to complement vaccination and enhance preparedness against emerging coronavirus variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs of Ministry of Education, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- The Ferrier Research Institute, Victoria University of Wellington, 69 Gracefield Road, Lower Hutt 5040, New Zealand.
- Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao 266003, China.
ORCID-Profile: Lihao Wang, Simon F R Hinkley, Guangli Yu, Chao Cai
Förderung
- the National Natural Science Foundation of China
- the Fundamental Research Funds for the Central Universities
- Taishan Scholar Climbing Project
- Taishan Scholar Young Project
- National Natural Science Foundation of China
- Young Project
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, L., Gao, L., Yang, C., Yin, M., Sun, J., Yang, L., Liu, C., Hinkley, S. F. R., Yu, G., & Cai, C. (2025). Precision-Engineered Dermatan Sulfate-Mimetic Glycopolymers for Multi-Targeted SARS-CoV-2 Inhibition. Marine Drugs. https://doi.org/10.3390/md23120486
Vancouver
Wang L, Gao L, Yang C, Yin M, Sun J, Yang L, et al. Precision-Engineered Dermatan Sulfate-Mimetic Glycopolymers for Multi-Targeted SARS-CoV-2 Inhibition. Marine Drugs. 2025. doi:10.3390/md23120486
BibTeX
@article{Wang2025,
author = {Wang, Lihao and Gao, Lei and Yang, Chendong and Yin, Mengfei and Sun, Jiqin and Yang, Luyao and Liu, Chanjuan and Hinkley, Simon F R and Yu, Guangli and Cai, Chao},
title = {Precision-Engineered Dermatan Sulfate-Mimetic Glycopolymers for Multi-Targeted SARS-CoV-2 Inhibition},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23120486}
}
EUVIMED